OR2M5

Across TCGA pan-cancer cohorts, OR2M5 Mutation is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated OR2M5 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR2M5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2M5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, BRCA, and OV are the cancer types where OR2M5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.010	0.784	<.001	24	view →
BRCA	OS	Median	All	0.592	0.924	<.001	22	view →
OV	OS	Median	II,III,IV	0.261	0.843	<.001	18	view →
BLCA	OS	Median	IV	0.142	0.604	<.001	15	view →
SKCM	DFS	Median	All	0.371	0.649	.007	15	view →
UCEC	DFS	Median	All	1.000	0.828	.012	14	view →
HNSC	OS	Median	All	0.238	0.606	.020	12	view →
LUAD	DFS	Median	All	0.123	0.356	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

OR2M5–LIHC (OS)

Open the LIHC breakdown →